Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study

MLA

Lulu Ye, et al. “Combined All‐trans Retinoic Acid with Low‐dose Apatinib in Treatment of Recurrent/Metastatic Head and Neck Adenoid Cystic Carcinoma: A Single‐center, Secondary Analysis of a Phase II Study.” Cancer Medicine, vol. 12, no. 8, Apr. 2023, pp. 9144–55. EBSCOhost, https://doi.org/10.1002/cam4.5653.

APA

Lulu Ye, Lin Zhang, Rongrong Li, Xinhua Pan, Jiang Li, Shengjin Dou, Wen Jiang, Chong Wang, Wantao Chen, & Guopei Zhu. (2023). Combined all‐trans retinoic acid with low‐dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single‐center, secondary analysis of a phase II study. Cancer Medicine, 12(8), 9144–9155. https://doi.org/10.1002/cam4.5653

Chicago

Lulu Ye, Lin Zhang, Rongrong Li, Xinhua Pan, Jiang Li, Shengjin Dou, Wen Jiang, Chong Wang, Wantao Chen, and Guopei Zhu. 2023. “Combined All‐trans Retinoic Acid with Low‐dose Apatinib in Treatment of Recurrent/Metastatic Head and Neck Adenoid Cystic Carcinoma: A Single‐center, Secondary Analysis of a Phase II Study.” Cancer Medicine 12 (8): 9144–55. doi:10.1002/cam4.5653.